- Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndromePaul L Chazot
Durham University, Centre for Integrative Neuroscience CINS, School of Biological and Biomedical Sciences, South Road, Durham DH1 3LE, UK
Curr Opin Investig Drugs 8:570-9. 2007..In March 2007, plans to develop the agent for the potential treatment of other cognitive disorders, such as Alzheimer's disease, were being finalized and testing was expected to begin before the end of that year...
- Immunohistochemical localization of N-methyl-D-aspartate receptor subunits in the adult murine hippocampal formation: evidence for a unique role of the NR2D subunitChristopher L Thompson
School of Biological and Biomedical Sciences, University of Durham, Science Research Laboratories, South Road, Durham, UK
Brain Res Mol Brain Res 102:55-61. 2002..Less intense staining was also observed in the internal third of the molecular layer of the dentate gyrus...
- Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2B-selective NMDA receptor antagonistsPaul L Chazot
Institute of Pharmacy, Chemistry and Biomedical Sciences, University of Sunderland, Sunderland, Tyne and Wear SR2 3SD, UK
Neuropharmacology 42:319-24. 2002....
- The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologiesPaul L Chazot
Sunderland Pharmacy School, University of Sunderland, Sunderland, Tyne and Wear SR2 3SD, UK
Curr Med Chem 11:389-96. 2004..The apparent superior preclinical and clinical data for the second and third generation NR2B compounds is likely to reflect subtype selectivity, a unique mode of action and cellular location of the NR2B receptors in the CNS...